BIOELECTRONICS CORPORATION Financials BioElectronics Corporation
Equities
BIEL
US09062H1086
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.00015 USD | -25.00% |
|
+100.00% | 0.00% |
| Mar. 25 | BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis Study | CI |
| Feb. 23 | Bioelectronics Corporation Announces the Publication of Pilot Study Results | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Capitalization 1 | 12.42 | 18.33 | 31.38 | 25.6 |
| Enterprise Value (EV) 1 | 24.33 | 31.09 | 44.44 | 38.94 |
| P/E ratio | -4 x | -7.55 x | -26.5 x | -95.5 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 11.9 x | 19.5 x | 37.8 x | 15.9 x |
| EV / Revenue | 23.3 x | 33 x | 53.6 x | 24.2 x |
| EV / EBITDA | -12.1 x | -23.8 x | -43.1 x | - |
| EV / FCF | -24 x | -42.7 x | -106 x | -70.3 x |
| FCF Yield | -4.17% | -2.34% | -0.94% | -1.42% |
| Price to Book | -0.96 x | -1.26 x | -2.12 x | -1.69 x |
| Nbr of stocks (in thousands) | 20,706,218 | 22,917,519 | 24,134,784 | 24,378,829 |
| Reference price 2 | 0.000600 | 0.000800 | 0.001300 | 0.001050 |
| Announcement Date | 8/11/20 | 8/11/20 | 4/7/22 | 4/7/22 |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Net sales 1 | 1.046 | 0.9418 | 0.8296 | 1.609 |
| EBITDA 1 | -2.008 | -1.305 | -1.032 | - |
| EBIT 1 | -2.01 | -1.306 | -1.033 | -0.1371 |
| Operating Margin | -192.19% | -138.68% | -124.5% | -8.52% |
| Earnings before Tax (EBT) 1 | -2.988 | -2.325 | -1.16 | -0.2898 |
| Net income 1 | -2.988 | -2.325 | -1.16 | -0.2898 |
| Net margin | -285.73% | -246.91% | -139.8% | -18.01% |
| EPS 2 | -0.000150 | -0.000106 | -0.000049 | -0.000011 |
| Free Cash Flow 1 | -1.014 | -0.7274 | -0.418 | -0.5543 |
| FCF margin | -96.91% | -77.23% | -50.39% | -34.44% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/11/20 | 8/11/20 | 4/7/22 | 4/7/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Net Debt 1 | 11.9 | 12.8 | 13.1 | 13.3 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | -5.93 x | -9.77 x | -12.66 x | - |
| Free Cash Flow 1 | -1.01 | -0.73 | -0.42 | -0.55 |
| ROE (net income / shareholders' equity) | 25.2% | 16.9% | 7.81% | 1.92% |
| ROA (Net income/ Total Assets) | -258% | -201% | -168% | -33.7% |
| Assets 1 | 1.156 | 1.159 | 0.6918 | 0.8607 |
| Book Value Per Share 2 | -0 | -0 | -0 | -0 |
| Cash Flow per Share 2 | 0 | 0 | 0 | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 8/11/20 | 8/11/20 | 4/7/22 | 4/7/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 3.71M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- BIEL Stock
- Financials BioElectronics Corporation
